$0.53
0.00%
Nasdaq, Fri, Sep 25 2026.
ISIN
US68236P1075
Symbol
ONCT

Oncternal Therapeutics Inc Stock price

$0.53
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
+0.00 0.00% 1Y
-5.69 91.53% 3Y
-91.27 99.43% 5Y
-1,063.47 99.95% 10Y
-12,739.47 100.00% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
+0.00 0.00%
ISIN
US68236P1075
Symbol
ONCT
Industry

Is Oncternal Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
81.8%
Return on Equity
-131.4%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $1.7m
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | 112.4%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
0.5%
Employees
29
Rev per Employee
$30.0k

Oncternal Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Oncternal Therapeutics Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Oncternal Therapeutics Inc forecast:

Hold
50%
Sell
50%

Financial data from Oncternal Therapeutics Inc

Sep '24
+/-
%
2.16 2.16
227% 227%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
3% 3%
571%
- Research and Development Expense 26 26
19% 19%
1,194%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -36 -36
18% 18%
-1,665%
Net Profit -35 -35
17% 17%
-1,601%

In millions USD.

Don't miss a Thing! We will send you all news about Oncternal Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.

Head office United States
CEO Mr. Breitmeyer
Employees 29
Founded 1997
Website www.oncternal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today